enGene secures $125 million expanded debt facility with Hercules Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 20, 2026 5:35 PM ESTUp to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer
$25 million advanced at close of the amendment to refinance existing debt facility
BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an amendment to an amended and restated loan and security agreement (as amended, the Loan Agreement) with two of its subsidiaries and Hercules Capital, Inc. (NYSE: HTGC) (Hercules), as... More
